Nicole Murphy - Feb 7, 2022 Form 3 Insider Report for BIOGEN INC. (BIIB)

Role: Head of Pharm Ops and Tech
Signature: /s/ Wendell Taylor, attorney in fact for Nicole Murphy
Stock symbol: BIIB
Transactions as of: Feb 7, 2022
Transactions value $: $0
Form type: 3
Date filed: 2/14/2022, 03:14 PM
Next filing: Feb 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BIIB	Common Stock						1.23K	Feb 7, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	825	$0.00	Direct	F1
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	131	$0.00	Direct	F2
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	718	$0.00	Direct	F3
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	1.51K	$0.00	Direct	F4
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	2.72K	$0.00	Direct	F5
holding	BIIB	Restricted Stock Unit							Feb 7, 2022	Common Stock	554	$0.00	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This award was granted to the reporting person on August 1, 2019 and will vest in full on August 1, 2022.
F2	This award was granted to the reporting person on December 2, 2019 an will vest in three equal installments on each anniversary of the grant date.
F3	This award was granted to the reporting person on April 1, 2021 and will vest in three equal installments on each anniversary of the grant date.
F4	This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F5	This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F6	This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).